Status:
COMPLETED
23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy
Lead Sponsor:
University of Sao Paulo
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
5-18 years
Phase:
PHASE4
Brief Summary
Objectives: To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in JIA patients with and without anti-TNF therapy. The influences of demographic data, dise...
Detailed Description
Seventeen JIA patients (International League Against Rheumatism criteria) followed at the Pediatric Rheumatology Unit of Children's Institute of Hospital das Clínicas da Faculdade de Medicina da Unive...
Eligibility Criteria
Inclusion
- Juvenile idiopathic arthritis criteria (International League Against Rheumatism criteria)
- ≥ 5 and ≤ 18 years old
Exclusion
- Previous vaccination against S. pneumoniae
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT02196480
Start Date
January 1 2008
End Date
June 1 2012
Last Update
July 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Dispensação de Medicamentos de Alto Custo (CEDMAC)
São Paulo, São Paulo, Brazil, 01246-903